In cervical cancer, Astrin can differentially regulate the mammalian target of rapamycin (mTOR) pathway in the process of tumor cell resistance to chemotherapeutic drugs including taxol (Yuan et al., 2014). This evidence concerns the gene MTOR and neoplasm.